| Identification | Back Directory | [Name]
HS-10296 | [CAS]
1899921-05-1 | [Synonyms]
HS-10296
Almonertinib
HS 10296;HS10296
Almonertinib (HS-10296)
HS-10296;HS 10296;HS10296;1899921-05-1
N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(meth)amino)-4-methoxyphenyl)acrylamide
N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
2-Propenamide, N-[5-[[4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]- | [Molecular Formula]
C30H35N7O2 | [MDL Number]
MFCD32173681 | [MOL File]
1899921-05-1.mol | [Molecular Weight]
525.64 |
| Chemical Properties | Back Directory | [density ]
1.24±0.1 g/cm3(Predicted) | [solubility ]
DMSO:91.67(Max Conc. mg/mL);174.38(Max Conc. mM)
Ethanol:6.0(Max Conc. mg/mL);11.41(Max Conc. mM) | [form ]
Solid | [pka]
12.68±0.70(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Almonertinib (HS-10296) is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib is used for the research of the non-small cell lung cancer. | [Mechanism of action]
Almonertinib inhibits EGFR tyrosine kinase targeting EGFR-sensitizing and T790M resistance mutations. |
|
|